Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items: 2011-2024

  • Heron Therapeutics' Non-cash Items rose 6899.27% to $9.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.6 million, marking a year-over-year increase of 6899.27%. This contributed to the annual value of $9.6 million for FY2024, which is 15.81% down from last year.
  • Latest data reveals that Heron Therapeutics reported Non-cash Items of $9.6 million as of Q4 2024, which was up 6,899.27% from $137,000 recorded in Q4 2023.
  • In the past 5 years, Heron Therapeutics' Non-cash Items registered a high of $69.1 million during Q4 2020, and its lowest value of $137,000 during Q4 2023.
  • Over the past 2 years, Heron Therapeutics' median Non-cash Items value was $4.9 million (recorded in 2023), while the average stood at $4.9 million.
  • Per our database at Business Quant, Heron Therapeutics' Non-cash Items tumbled by 97.54% in 2021 and then spiked by 6,899.27% in 2024.
  • Quarterly analysis of 4 years shows Heron Therapeutics' Non-cash Items stood at $69.1 million in 2020, then slumped by 97.54% to $1.7 million in 2021, then reached $137,000 in 2023, then spiked by 6,899.27% to $9.6 million in 2024.
  • Its Non-cash Items stands at $9.6 million for Q4 2024, versus $137,000 for Q4 2023 and $1.7 million for Q4 2021.